In its statement, GSK said the $30 billion investment would include capital investments in its U.S. supply chain and more ...

British pharma contender GlaxoSmithKline ($GSK) is striving to regain relevance in a field long overshadowed by its rivals ...

The pharmaceutical company plans to break ground on a new manufacturing facility in Upper Merion, Pennsylvania, in 2026.

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. | British Big Pharma GSK is ...

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

GSK commits $30 billion investment in U.S. R&D and manufacturing during Trump’s UK state visit, strengthening its focus on ...

GSK is leaning hard into its U.S. footprint with a $30 billion commitment over the next five yearsan investment wave that ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...